FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891619067> ?p ?o ?g. }

• W2891619067 endingPage "1800897" @default.
• W2891619067 startingPage "1800897" @default.
• W2891619067 abstract "Alpha-1 antitrypsin deficiency (AATD) is a hereditary disorder characterised by an abnormally low concentration of functional alpha-1 antitrypsin (AAT) in blood and tissues [1]. The primary role of AAT is to protect elastin-containing tissues, most notably the lung, against the destructive activity of proteolytic enzymes [2]. Patients with severe AATD present with serum AAT concentrations below 11 µM and are prone to destruction of the lung tissue, often developing respiratory symptoms and emphysema in the fourth or fifth decade of life [3, 4].Footnotes This manuscript has recently been accepted for publication in the European Respiratory Journal . It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Greulich reports personal fees from AstraZeneca, personal fees from Boehringer-Ingelheim, personal fees from Chiesi, personal fees from CSL-Behring, grants and personal fees from Grifols, personal fees from GSK, personal fees from Mundipharma, personal fees from Novartis, outside the submitted work.Conflict of interest: Dr. Chlumsky reports personal fees from honoraria for lectures organized by CSL Behring, personal fees from honoraria for lectures organized by Boehringer Ingelheim, outside the submitted work.Conflict of interest: Dr. Wencker is a consultant to CSL Behring.Conflict of interest: Mr. Vit reports no other conflicts of interest outside of his employment with CSL Behring during the conduct of the study.Conflict of interest: Dr. Fries reports no other conflicts of interest outside of his employment with CSL Behring during the conduct of the study.Conflict of interest: Dr. Chung reports no other conflicts of interest outside of his employment with CSL Behring during the conduct of the study.Conflict of interest: Dr. Shebl reports no other conflicts of interest outside of his employment with CSL Behring during the conduct of the study.Conflict of interest: Dr. Vogelmeier reports grants and personal fees from AstraZeneca, grants and personal fees from Boehringer Ingelheim, personal fees from CSL Behring, personal fees from Chiesi, grants and personal fees from GlaxoSmithKline, grants and personal fees from Grifols, personal fees from Menarini, personal fees from Mundipharma, grants and personal fees from Novartis, personal fees from Teva, personal fees from Cipla, grants from Bayer-Schering, grants from MSD, grants from Pfizer, outside the submitted work.Conflict of interest: Dr. Chapman reports grants and personal fees from AstraZeneca, grants and personal fees from BoehringerIngelheim, grants from Baxter, grants and personal fees from CSL Behring, grants and personal fees from Grifols, grants from GlaxoSmithKline, grants and personal fees from Sanofi, grants and personal fees from Genentech, grants and personal fees from Kamada, grants from Amgen, grants and personal fees from Roche, grants and personal fees from Novartis, personal fees from Merck, personal fees from CIHR-GSK Research Chair in Respiratory Health Care Delivery, UHN, grants from Shire, grants from Octapharma, during the conduct of the study.Conflict of interest: Dr. McElvaney reports grants from CSL Behring, during the conduct of the study; personal fees from CSL behring, outside the submitted work." @default.
• W2891619067 created "2018-09-27" @default.
• W2891619067 creator A5001151898 @default.
• W2891619067 creator A5012528779 @default.
• W2891619067 creator A5025097301 @default.
• W2891619067 creator A5034535949 @default.
• W2891619067 creator A5036017418 @default.
• W2891619067 creator A5044161269 @default.
• W2891619067 creator A5049535547 @default.
• W2891619067 creator A5059684830 @default.
• W2891619067 creator A5072466438 @default.
• W2891619067 creator A5072678137 @default.
• W2891619067 date "2018-09-20" @default.
• W2891619067 modified "2023-10-11" @default.
• W2891619067 title "Safety of biweekly α₁-antitrypsin treatment in the RAPID programme" @default.
• W2891619067 cites W102357629 @default.
• W2891619067 cites W1829394506 @default.
• W2891619067 cites W1998442642 @default.
• W2891619067 cites W1999650160 @default.
• W2891619067 cites W2030201588 @default.
• W2891619067 cites W2044661074 @default.
• W2891619067 cites W2119128997 @default.
• W2891619067 cites W2121496322 @default.
• W2891619067 cites W2135677683 @default.
• W2891619067 cites W2233119733 @default.
• W2891619067 cites W2416046075 @default.
• W2891619067 cites W2416134252 @default.
• W2891619067 cites W2558038905 @default.
• W2891619067 cites W2733163186 @default.
• W2891619067 cites W2773851838 @default.
• W2891619067 cites W4211049690 @default.
• W2891619067 doi "https://doi.org/10.1183/13993003.00897-2018" @default.
• W2891619067 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6557539" @default.
• W2891619067 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30237305" @default.
• W2891619067 hasPublicationYear "2018" @default.
• W2891619067 type Work @default.
• W2891619067 sameAs 2891619067 @default.
• W2891619067 citedByCount "8" @default.
• W2891619067 countsByYear W28916190672018 @default.
• W2891619067 countsByYear W28916190672019 @default.
• W2891619067 countsByYear W28916190672020 @default.
• W2891619067 countsByYear W28916190672021 @default.
• W2891619067 countsByYear W28916190672022 @default.
• W2891619067 crossrefType "journal-article" @default.
• W2891619067 hasAuthorship W2891619067A5001151898 @default.
• W2891619067 hasAuthorship W2891619067A5012528779 @default.
• W2891619067 hasAuthorship W2891619067A5025097301 @default.
• W2891619067 hasAuthorship W2891619067A5034535949 @default.
• W2891619067 hasAuthorship W2891619067A5036017418 @default.
• W2891619067 hasAuthorship W2891619067A5044161269 @default.
• W2891619067 hasAuthorship W2891619067A5049535547 @default.
• W2891619067 hasAuthorship W2891619067A5059684830 @default.
• W2891619067 hasAuthorship W2891619067A5072466438 @default.
• W2891619067 hasAuthorship W2891619067A5072678137 @default.
• W2891619067 hasBestOaLocation W28916190671 @default.
• W2891619067 hasConcept C71924100 @default.
• W2891619067 hasConceptScore W2891619067C71924100 @default.
• W2891619067 hasIssue "5" @default.
• W2891619067 hasLocation W28916190671 @default.
• W2891619067 hasLocation W28916190672 @default.
• W2891619067 hasLocation W28916190673 @default.
• W2891619067 hasLocation W28916190674 @default.
• W2891619067 hasOpenAccess W2891619067 @default.
• W2891619067 hasPrimaryLocation W28916190671 @default.
• W2891619067 hasRelatedWork W1489783725 @default.
• W2891619067 hasRelatedWork W1506200166 @default.
• W2891619067 hasRelatedWork W2039318446 @default.
• W2891619067 hasRelatedWork W2048182022 @default.
• W2891619067 hasRelatedWork W2080531066 @default.
• W2891619067 hasRelatedWork W2604872355 @default.
• W2891619067 hasRelatedWork W2748952813 @default.
• W2891619067 hasRelatedWork W2899084033 @default.
• W2891619067 hasRelatedWork W3032375762 @default.
• W2891619067 hasRelatedWork W3108674512 @default.
• W2891619067 hasVolume "52" @default.
• W2891619067 isParatext "false" @default.
• W2891619067 isRetracted "false" @default.
• W2891619067 magId "2891619067" @default.
• W2891619067 workType "article" @default.